NewEdge Advisors LLC Grows Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

NewEdge Advisors LLC raised its holdings in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 16.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 104,650 shares of the medical research company's stock after acquiring an additional 14,683 shares during the quarter. NewEdge Advisors LLC's holdings in Edwards Lifesciences were worth $7,747,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Virtu Financial LLC bought a new stake in shares of Edwards Lifesciences in the third quarter worth about $3,173,000. World Investment Advisors LLC raised its holdings in shares of Edwards Lifesciences by 1,660.7% during the 3rd quarter. World Investment Advisors LLC now owns 72,277 shares of the medical research company's stock worth $4,770,000 after acquiring an additional 68,172 shares in the last quarter. Wilmington Savings Fund Society FSB boosted its position in shares of Edwards Lifesciences by 147.0% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 9,106 shares of the medical research company's stock valued at $601,000 after acquiring an additional 5,420 shares during the last quarter. Destination Wealth Management grew its holdings in shares of Edwards Lifesciences by 2.8% in the third quarter. Destination Wealth Management now owns 7,012 shares of the medical research company's stock valued at $463,000 after purchasing an additional 193 shares in the last quarter. Finally, Tidal Investments LLC increased its position in Edwards Lifesciences by 0.7% in the third quarter. Tidal Investments LLC now owns 39,532 shares of the medical research company's stock worth $2,609,000 after purchasing an additional 275 shares during the last quarter. Institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Stock Down 3.2 %

EW stock traded down $2.30 during trading on Monday, reaching $69.23. 3,767,362 shares of the company traded hands, compared to its average volume of 4,926,556. The business has a 50 day simple moving average of $71.18 and a 200 day simple moving average of $70.95. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $95.25. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The company has a market capitalization of $40.70 billion, a price-to-earnings ratio of 9.93, a price-to-earnings-growth ratio of 4.82 and a beta of 1.15.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. On average, equities research analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Scott B. Ullem sold 11,250 shares of the business's stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $75.76, for a total transaction of $852,300.00. Following the sale, the chief financial officer now directly owns 30,561 shares of the company's stock, valued at $2,315,301.36. The trade was a 26.91 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Daniel J. Lippis sold 400 shares of Edwards Lifesciences stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $69.48, for a total value of $27,792.00. Following the sale, the vice president now directly owns 22,588 shares of the company's stock, valued at approximately $1,569,414.24. This represents a 1.74 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 71,853 shares of company stock worth $5,163,062. Insiders own 1.29% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Stifel Nicolaus raised shares of Edwards Lifesciences from a "hold" rating to a "buy" rating and lifted their price objective for the stock from $75.00 to $90.00 in a research note on Thursday, January 30th. Royal Bank of Canada restated an "outperform" rating and set a $85.00 price objective on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. Morgan Stanley raised their price objective on Edwards Lifesciences from $70.00 to $75.00 and gave the company an "equal weight" rating in a research note on Wednesday, February 12th. Wolfe Research lowered Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a report on Wednesday, February 12th. Finally, Truist Financial lowered their target price on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating for the company in a report on Friday, April 11th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and ten have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $78.55.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.